Thursday, September 04, 2014 2:39:25 PM
The man is brilliant! Hat's off to you Richard!
8-K 1 d783886d8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 27, 2014
PUMA BIOTECHNOLOGY, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 001-35703 77-0683487
(State or other jurisdiction of incorporation)Commission File Number) (IRS Employer
Identification No.)
10880 Wilshire Boulevard, Suite 2150
Los Angeles, California 90024
(Address of principal executive offices) (Zip Code)
(424) 248-6500
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 27, 2014, Dr. Richard B. Phillips, Senior Vice President, Regulatory Affairs, Quality Assurance and Pharmacovigilance, notified Puma Biotechnology, Inc. (“Puma” or the “Company”) that he will be retiring for health reasons effective during the fourth quarter of 2014 (and no later than November 7, 2014).
Effective upon Dr. Phillips’ departure, his regulatory responsibilities will be assumed by Erin Jones, the Company’s current Vice President, Global Regulatory Affairs. Prior to joining Puma, Mr. Jones worked at Genentech, where he held a variety of positions including North America Oncology Team Leader, HER Franchise Group Leader and Head of Regulatory Intelligence. In his roles at Genentech, Mr. Jones oversaw the HER mechanism franchise, where he led and oversaw the late-stage development and BLA submission for TDM1 (Kadcyla™) and Perjeta™ in HER2-positive metastatic breast cancer, and obtained approvals for trastuzumab (HERCEPTIN™) in HER2 positive adjuvant breast cancer. These regulatory leadership activities also included direct negotiation with regulatory health authorities worldwide as well as leading FDA ODAC interactions.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PUMA BIOTECHNOLOGY, INC.
Date: September 3, 2014 By:
/s/ Alan H. Auerbach
Alan H. Auerbach
Chief Executive Officer and President
Recent PBYI News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 01:01:05 PM
- Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 09/03/2024 08:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/27/2024 09:02:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 01:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 01:00:09 PM
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/06/2024 09:23:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:41:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:17:49 PM
- Puma Biotechnology Reports Second Quarter Financial Results • Business Wire • 08/01/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 11:11:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 11:06:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 10:57:18 PM
- Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results • Business Wire • 07/18/2024 08:10:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/18/2024 12:43:05 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/18/2024 12:39:26 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/18/2024 12:36:50 AM
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 07/02/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:27:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:25:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:23:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:18:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/14/2024 01:46:47 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/14/2024 01:44:55 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/14/2024 01:43:51 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/14/2024 01:41:17 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM